The Motley Fool Discussion Boards

Previous Page

Industry Discussions / Biotechnology


Subject:  NKTX Date:  7/10/2020  1:25 PM
Author:  MDIRADS Number:  25367 of 25444

Nkarta (NKTX) IPO’d today. The company is involved in natural killer (NK) cells for treatment of hematologic malignancies. I caught the tail end of an interview with Cavuto today on FBN. Does anyone have any insight into this technology?
Copyright 1996-2020 trademark and the "Fool" logo is a trademark of The Motley Fool, Inc. Contact Us